PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 186 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 1.04 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $1,832,000 | -51.4% | 56,709 | -48.5% | 0.00% | -50.0% |
| Q3 2016 | $3,773,000 | +389.4% | 110,216 | +382.5% | 0.00% | – |
| Q2 2016 | $771,000 | -36.9% | 22,844 | -0.9% | 0.00% | -100.0% |
| Q1 2016 | $1,221,000 | -18.8% | 23,054 | +17.7% | 0.00% | 0.0% |
| Q4 2015 | $1,504,000 | +92.8% | 19,582 | +3.1% | 0.00% | – |
| Q3 2015 | $780,000 | -21.2% | 18,996 | +35.8% | 0.00% | -100.0% |
| Q2 2015 | $990,000 | -23.5% | 13,993 | -3.9% | 0.00% | 0.0% |
| Q1 2015 | $1,294,000 | +57.6% | 14,564 | +57.2% | 0.00% | – |
| Q4 2014 | $821,000 | -76.9% | 9,267 | -74.8% | 0.00% | -100.0% |
| Q3 2014 | $3,557,000 | +530.7% | 36,707 | +498.7% | 0.00% | – |
| Q2 2014 | $564,000 | -52.7% | 6,131 | -64.0% | 0.00% | -100.0% |
| Q1 2014 | $1,192,000 | +92.3% | 17,024 | +57.7% | 0.00% | – |
| Q4 2013 | $620,000 | +108.8% | 10,794 | +75.0% | 0.00% | – |
| Q3 2013 | $297,000 | +471.2% | 6,169 | +242.0% | 0.00% | – |
| Q2 2013 | $52,000 | – | 1,804 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |